Preventive care in chronic liver disease
10.1046/j.1525-1497.1999.11188.x Cite this article as: Riley, T.R. & Smith, J.P. J GEN INTERN MED (1999) 14: 699. doi:10.1046/j.1525-1497.1999.11188.x Abstract OBJECTIVE: To identify preventive care measures that are appropriate for and specific to patients with chronic liver disease and to provide recommendations and information that can be shared with patients. MEASUREMENTS: A review of the literature was undertaken using MEDLINE from 1970 to present. Priority was given to randomized controlled studies, but case reports, case-control studies, and reviews were included. MAIN RESULTS: Evidence for the avoidance of alcohol and other toxic substances, immunizations, and dietary modifications for chronic liver disease is summarized. In addition, measures that are effective in the mitigation of the complications of cirrhosis are reviewed. CONCLUSIONS: Preventive care can play an important role in patients with chronic liver diseases. Based on the existing data, the preventive strategies of alcohol avoidance, hepatitis vaccination, avoidance of NSAIDs nonsteroidal anti-inflammatory drugs, iron supplementation when appropriate, and a low-fat diet are prudent in patients with chronic liver disease. Once cirrhosis develops, screening for hepatocellular cancer with α-fetoprotein testing and ultrasound, and screening for varices by endoscopy are justified. Key Words liver diseases prevention hepatitis cirrhosis immunization diet References
Alter JM, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med. 1992;327:1899–905.
Zein NN, Rakela J, Krawitt EL, et al. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Ann Intern Med. 1996;125:634–9.
Poupon RE, Balkau B, Eschwege E, et al. A multicenter, controlled trial of ursodial for the treatment of primary biliary cirrhosis. N Engl J Med. 1991;324:1548–54.
Propst A, Propst T, Zangerl G, et al. Prognosis and life expectancy in chronic liver disease. Dig Dis Sci. 1995;40:1805–15.
Thun MJ, Peto R, Lopez AD, et al. Alcohol consumption and mortality among middle-aged and elderly U.S. adults. N Engl J Med. 1997;337:1705–14.
Scheig R. Effects of ethanol on the liver. Am J Clin Nutr. 1970;23:467–73.
Corrao G, Arico S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology. 1998;27:914–9.
O’Conner PG, Schottenfeld RS. Patients with alcohol problems. N Engl J Med. 1998;592–601.
Wang JY, Lee SD, Tsai YT, et al. Fulminant hepatitis A in chronic HBV carrier. Dig Dis Sci. 1986;31:109–11.
Conteas C, Kao H, Rakela J, et al. Acute type A hepatitis in three patients with chronic HBV infection. Dig Dis Sci. 1983;28:684–6.
Keeffe EB. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol. 1995;90:201–5.
Akriviadis EA, Redeker AG. Fulminant hepatitis A in intravenous drug users with chronic liver disease. Ann Intern Med. 1989;110:838–9.
Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med. 1998;338:286–90.
Francis DP. The public’s health unprotected: reversing a decade of underutilization of hepatitis B vaccine. JAMA. 1995;274:1242–3.
Bader TF. Hepatitis A vaccine. Am J Gastroenterol. 1996;91:217–22.
Gardner P, Eickoff T, Poland GA, et al. Adult immunizations. Ann Intern Med. 1996;12:35–40.
Keeffe EB, Iwarson S, McMahon BJ, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology. 1998;27:881–6.
Hess G, Clemens R, Bienzle U, et al. Immunogenicity and safety of an inactivated hepatitis A vaccine in anti-HIV positive and negative homosexual men. J Med Virol. 1995;46:40–2.
Andre FE. Summary of safety and efficacy data on a yeast-derived hepatitis vaccine. Am J Med. 1989;87(3A):14S-20S.
Hughes JM. Prevention of pneumococcal disease. MMWR. 1997;46:1–24.
Hughes JM. Prevention and control of influenza. MMWR. 1997;46:1–25.
Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 1995;118–27.
Speeg KV, Bay MK. Prevention and treatment of drug-induced liver disease. Gastroenterol Clin North Am. 1995;24:1047–64.
Carson JL, Willet LR. Toxicity of nonsteroidal anti-inflammatory drugs: an overview of the epidemiological evidence. Drugs. 1993;46S:243–8.
Riley TR, Smith JP. Ibuprofen-induced hepatotoxicity in those with chronic hepatitis C: a case series. Am J Gastroenterol. 1998;93:1563–5.
Rabinovitz M, Van Thiel DH. Hepatotoxicity of nonsteroidal antiinflammatory drugs. Am J Gastroenterol. 1992;87:1696–1704.
Zimmerman HJ, Maddrey WC. Acetaminophen hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology. 1995;22:767–73.
Flora K, Hahn M, Rosen H, et al. Milk thistle (
) for the therapy of liver disease. Am J Gastroenterol. 1998;93:139–43.
Bashir RM, Lewis JH. Hepatotoxicity of drugs used in the treatment of gastrointestinal disorders. Gastroenterol Clin North Am. 1995;24:937–67.
Riggio O, Montagnese F, Fiore P, et al. Iron overload in patients with chronic viral hepatitis: how common is it? Am J Gastroenterol. 1997;8:1298–1301.
Bisceglie AM, Axiotis CA, Hoofnagle JH, et al. Measurement of iron status in patients with chronic hepatitis. Gastroenterology. 1992;102:2108–13.
Olynyk JK, Reddy R, Di Bisceglie AM, et al. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology. 1995;108:1104–9.
Van Thiel DH, Friedlander L, Fagiuoli S, et al. Response to interferon alpha therapy is influenced by the iron content of the liver. J Hepatol. 1994;20:410–5.
Hayashi H, Takikawa T, Nishimura N, et al. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol. 1994;89:986–8.
Guptas RC, Mulhotra S, Lehandekar P, et al. Influence of low iron diet on the efficacy of interferon therapy in patients with chronic liver disease. Presented at the IXth Biennial Scientific Meeting Asian Pacific Association for the Study of the Liver, Kuala Lumpur, Malaysia, January 26–29, 1994.
Stal P, Hultcrantz R. Iron increases ethanol toxicity in rat liver. J Hepatol. 1993;17:108–15.
Laurin J, Lindor KD, Crippin JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology. 1996;23:1464–7.
Powell EE, Cooksley WG, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11:74–80.
Bacon BR, Farahvash MJ, Janney CG, et al. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994;107:1103–9.
Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet in obese patients with fatty liver. J Hepatol. 1997;27:103–7.
Deems RO, Friedman LS, Friedman MI, et al. Relationship between liver biochemical tests and dietary intake in patients with liver disease. J Clin Gastroenterol. 1994;18:304–8.
Kleber G, Hasan A, Sauerbruch T. Prophylaxis of first variceal bleeding. Bailliere Clin Gastroenterol. 1992;6:563–80.
DeFranchis R. Prediction of first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med. 1988;319:983–9.
Poynard T, Cales P, Pasta L, et al. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. N Engl J Med. 1991;324: 1532–8.
Grace N. Prevention of initial variceal hemorrhage. Gastroenterol Clin North Am. 1992;21:149–61.
Angelico M, Carli L, Piat C, et al. Isosorbide-5-mononitrate versus propranolol in the prevention of first bleeding in cirrhosis. Gastroenterology. 1993;104:1460–5.
Zoli M, Magalotti D, Bianchi G, et al. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer. 1996;78:977–85.
Iwatsuki S, Starzl TE, Sheahan DG, et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg. 1991;214:221–9.
Maringhini A, Cottone M, Sciarrino E, et al. Ultrasonography and alpha-fetoprotein, in diagnosis of hepatocellular carcinoma in cirrhosis. Dig Dis Sci. 1988;33:47–51.
Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.
Durand F, Buffet C, Pelleetier G, et al. Screening of hepatocellular carcinoma in French patients. Dig Dis Sci. 1995;40:706–7.
Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology. 1998;27:273–8.
Such J, Runyon BA. Spontaneous bacterial peritonitis. Clin Infect Dis. 1998;27:669–76.
Gines P, Rimola A, Planus R, et al. Norfloxacin prevents bacterial infection in cirrhosis: results of a double-blind, placebo controlled trial. Hepatology. 1990;12:716–24.
Campillo B, Dupeyron C, Richardet JP, et al. Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effects of long term administration of norfloxacin. Clin Infect Dis. 1998;26:1066–70.
PubMed Copyright information
© Society of General Internal Medicine 1999